When the news arrived in August that what could be the first personalized mRNA cancer vaccine had succeeded in a late-stage clinical trial in melanoma, oncologists and the public alike were exhilarated. And that was before its makers had even disclosed just how well the therapy worked.
Experimental mRNA vaccine cuts risk melanoma returns by 42% | CNN
When the news arrived in August that what could be the first personalized mRNA cancer vaccine had succeeded in a late-stage clinical trial in melanoma, oncologists and the public alike were exhilarated. And that was before its makers had even disclosed just how well the therapy worked.
Merck and Moderna released results of a late-stage trial that showed an experimental mRNA vaccine slashed the risk that melanoma returns by 42%.
Ziad M. El-Zaatari/Science Photo Library/Getty Images
See all topics
Email
Link Copied!
